Abstract
The dual-specificity phosphatase PTEN functions as a tumor suppressor by hydrolyzing PI(3,4,5)P3 to PI(4,5)P2 to inhibit PI3K-AKT signaling and cellular proliferation. P-Rex2 is a guanine nucleotide exchange factor for Rho GTPases and can be activated by Gβ γsubunits downstream of G protein–coupled receptor signaling and by PI(3,4,5)P3 downstream of receptor tyrosine kinases. The PTEN:P-Rex2 complex is a commonly mutated signaling node in metastatic cancer. Assembly of the PTEN:P-Rex2 complex inhibits the activity of both proteins, and its dysregulation can drive PI3K-AKT signaling and cellular proliferation. Here, using cross-linking mass spectrometry and functional studies, we gained mechanistic insights into PTEN:P-Rex2 complex assembly and coinhibition. We found that PTEN was anchored to P-Rex2 by interactions between the PDZ-interacting motif in the PTEN C-terminal tail and the second PDZ domain of P-Rex2. This interaction bridged PTEN across the P-Rex2 surface, preventing PI(3,4,5)P3 hydrolysis. Conversely, PTEN both allosterically promoted an autoinhibited conformation of P-Rex2 and blocked its binding to Gβγ. In addition, we observed that the PTEN-deactivating mutations and P-Rex2 truncations combined to drive Rac1 activation to a greater extent than did either single variant alone. These insights enabled us to propose a class of gain-of-function, cancer-associated mutations within the PTEN:P-Rex2 interface that uncouple PTEN from the inhibition of Rac1 signaling.
| Original language | English |
|---|---|
| Article number | eabc4078 |
| Number of pages | 16 |
| Journal | Science Signaling |
| Volume | 14 |
| Issue number | 681 |
| DOIs | |
| Publication status | Published - 4 May 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Projects
- 5 Finished
-
Structural characterisation of the co-inhibitory complex formed by the tumour suppressor PTEN and the metastatic factor PREX2
Ellisdon, A. (Primary Chief Investigator (PCI)), Elmlund, H. (Chief Investigator (CI)) & Halls, M. (Chief Investigator (CI))
1/01/18 → 31/12/20
Project: Research
-
Structural and functional characterisation of the oncogene P-Rex1
Ellisdon, A. (Primary Chief Investigator (PCI)), Whisstock, J. (Chief Investigator (CI)), Elmlund, H. (Chief Investigator (CI)) & Halls, M. (Chief Investigator (CI))
1/01/17 → 31/12/19
Project: Research
-
Characterisation of a novel oncogene in breast cancer
Mitchell, C. (Primary Chief Investigator (PCI)), Ellisdon, A. (Chief Investigator (CI)) & McLean, C. (Chief Investigator (CI))
NHMRC - National Health and Medical Research Council (Australia)
1/01/16 → 31/12/21
Project: Research
Equipment
-
Monash Proteomics & Metabolomics Platform (MPMP)
Schittenhelm, R. (Other) & Steer, D. (Manager)
Faculty of Medicine Nursing and Health Sciences Research PlatformsFacility/equipment: Facility
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver